Diabetes Care, Vol 22, Issue 10 1607-1611, Copyright © 1999 by American Diabetes Association

ARTICLES

Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group

SR Heller, SA Amiel and P Mansell
Northern General Hospital, Sheffield, U.K. s.heller@sheffield.ac.uk

OBJECTIVE: To measure the effectiveness of insulin lispro, a fast-acting insulin analog, in reducing hypoglycemic episodes when used in a basal bolus regimen by patients with type 1 diabetes using intensive insulin therapy. RESEARCH DESIGN AND METHODS: In 11 diabetes outpatient clinics in the U.K., 165 subjects with type 1 diabetes were enrolled in a randomized crossover open-label study with a 2-month run-in period and then treated with a basal bolus regimen. Patients used human NPH insulin at night with either premeal insulin lispro for 4 months followed by human regular insulin for another 4 months or human regular insulin for 4 months followed by insulin lispro for another 4 months. The main outcome measures were the number of hypoglycemic episodes during both treatments and HbA1c level. RESULTS: A total of 135 patients were randomized, with 68 receiving insulin lispro and 67 receiving human regular insulin for the first 4 months. The data for the first 4 months of treatment only were compared as two independent groups because of a period effect and a treatment-period interaction. Glycemic control was equally tight during treatment with human regular insulin (HbA1c, 6.2 +/- 0.8%) and insulin lispro (6.0 +/- 0.9%). A total of 1,156 hypoglycemic episodes occurred during treatment with human regular insulin compared with 775 hypoglycemic episodes that occurred during treatment with insulin lispro (P = 0.04). This difference was chiefly because of a reduced number of nocturnal episodes (181 vs. 52, P = 0.001) in the insulin lispro group. CONCLUSIONS: The use of a fast-acting insulin analog, insulin lispro, as part of a basal bolus regimen reduces nocturnal hypoglycemia in patients with type 1 diabetes who maintain tight glycemic control during intensive insulin therapy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. J. Briscoe and S. N. Davis Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management Clin. Diabetes, July 1, 2006; 24(3): 115 - 121. [Abstract] [Full Text] [PDF]

				J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]

				M. K. Bulsara, C. D. J. Holman, E. A. Davis, and T. W. Jones The Impact of a Decade of Changing Treatment on Rates of Severe Hypoglycemia in a Population-Based Cohort of Children With Type 1 Diabetes Diabetes Care, October 1, 2004; 27(10): 2293 - 2298. [Abstract] [Full Text] [PDF]

				K. B. Campbell and S. S. Braithwaite Hospital Management of Hyperglycemia Clin. Diabetes, April 1, 2004; 22(2): 81 - 88. [Full Text] [PDF]

				K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]

				B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]

				J. Brand-Miller, S. Hayne, P. Petocz, and S. Colagiuri Low-Glycemic Index Diets in the Management of Diabetes: A meta-analysis of randomized controlled trials Diabetes Care, August 1, 2003; 26(8): 2261 - 2267. [Abstract] [Full Text] [PDF]

				J. E. Gerich Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia Arch Intern Med, June 9, 2003; 163(11): 1306 - 1316. [Abstract] [Full Text] [PDF]

				P. E. Cryer, S. N. Davis, and H. Shamoon Hypoglycemia in Diabetes Diabetes Care, June 1, 2003; 26(6): 1902 - 1912. [Abstract] [Full Text] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				A. B. King and D. Armstrong A Comparison of Basal Insulin Delivery: Continuous subcutaneous insulin infusion versus glargine Diabetes Care, April 1, 2003; 26(4): 1322 - 1322. [Full Text] [PDF]

				M. Kalergis, A. Schiffrin, R. Gougeon, P. J.H. Jones, and J.-F. Yale Impact of Bedtime Snack Composition on Prevention of Nocturnal Hypoglycemia in Adults With Type 1 Diabetes Undergoing Intensive Insulin Management Using Lispro Insulin Before Meals: A randomized, placebo-controlled, crossover trial Diabetes Care, January 1, 2003; 26(1): 9 - 15. [Abstract] [Full Text] [PDF]

				A. W. Norris and L. M.B. Laffel Avoiding Nocturnal Hypoglycemia: Consideration of an Extra Injection at Bedtime Ann Intern Med, April 2, 2002; 136(7): 547 - 549. [Full Text] [PDF]

				A. M.E. Stades, J. B.L. Hoekstra, I. van den Tweel, D. W. Erkelens, and F. Holleman Additional Lunchtime Basal Insulin During Insulin Lispro Intensive Therapy in a Randomized, Multicenter, Crossover Study in Adults : A real-life design Diabetes Care, April 1, 2002; 25(4): 712 - 717. [Abstract] [Full Text] [PDF]

				B. Bode, R. Weinstein, D. Bell, J. McGill, D. Nadeau, P. Raskin, J. Davidson, R. Henry, W.-C. Huang, and R. R. Reinhardt Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion: A randomized study in type 1 diabetes Diabetes Care, March 1, 2002; 25(3): 439 - 444. [Abstract] [Full Text] [PDF]

				P. E. Cryer and B. P. Childs Negotiating the Barrier of Hypoglycemia in Diabetes Diabetes Spectr, January 1, 2002; 15(1): 20 - 27. [Abstract] [Full Text] [PDF]

				M. Saleh and G. Grunberger Hypoglycemia: An Excuse for Poor Glycemic Control? Clin. Diabetes, October 1, 2001; 19(4): 161 - 167. [Abstract] [Full Text] [PDF]

				Additional articles abstracted in ACP Journal Club Evid. Based Med., May 1, 2000; 5(3): 67 - 67. [Full Text]